Daily Digest 2026-03-08

Top items from the CED news pipeline.

1. (97) Alabama Medical Cannabis Sales Gear for Spring 2026 Launch
2. (97) Cannabis compounds CBD and CBG may help reverse fatty liver disease, study finds
3. (97) From Billion-Dollar Hemp Drinks to FDA Cease-and-Desist Letters: The Cannabis Industry’s …
4. (97) Cannabis Compounds CBD and CBG Show Promise in Reducing Liver Fat and Improving …
5. (96) New Cannabis Group Will Help Ground Policy In Science And Patient Experience As …
6. (96) New Top Cannabis Regulator Sets Priorities In First Board Meeting
7. (95) Brazil’s Cannabis Crossroads: New Rules, Old Truths, and the Road Ahead
8. (95) 2 Greater Cincinnati breweries file lawsuit over Ohio ban on THC beverages – WLWT
9. (95) New Ohio law means THC-infused drinks won’t be available on many store shelves – WTVG
10. (95) Lawmakers strike down bill capping THC levels in Oregon’s cannabis edibles – Yahoo
11. (95) Attempt to limit potency of THC in marijuana edibles fails at Oregon Legislature
12. (95) Cannabis Compounds CBD and CBG Slash Liver Fat and Restore Metabolic Health
13. (95) Cannabinoid Oral Mucosal Delivery: Approaches to Formulation, Fabrication, and … – PubMed
14. (95) Study: CBD-Dominant Cannabis Products Provide Significant Anxiety Relief – NORML
15. (95) Clinical Trial: Cannabis Extracts Significantly Reduce Myofascial Pain – NORML
16. (95) As a Medical Cannabis Patient, I’m Watching This Supreme Court Case Closely
17. (95) The Week in Weed: March 2026 | Seyfarth Shaw LLP – JDSupra
18. (95) Marijuana gummies sold in Ohio recalled. Why, where they were sold – The Columbus Dispatch
19. (95) New Group Launches Ahead of Medicare CBD Pilots – Cannabis Wire
20. (95) Marijuana Status Based Prohibition Tag Archives – Powers Law Firm PA
21. (95) Louisiana lawmaker files bill to legalize recreational marijuana through licensed dispensaries
22. (92) Mom’s homemade medical cannabis recipe now being sold at Georgia dispensaries
23. (92) Ohio THC drink ban draws lawsuit from Cincinnati breweries
24. (92) Israeli researchers find cannabis compounds could lead to 1st drug for fatty liver disease
25. (92) Virginia adult-use sales bills pass both chambers, head to conference committee! – Blog
26. (92) Study highlights pros, cons of medical marijuana as its future in Tennessee remains unknown
27. (90) 2026 Utah legislature on cannabis, psychedelics and kratom – Fox 13
28. (90) Oregon Bill To Ban Marijuana Edibles With More Than 10 Milligrams Of THC Fails
29. (88) Georgia bill could limit probable cause for smell of marijuana, cannabis, or hemp – YouTube
30. (85) Study reveals cannabis compounds reduce threat of fatty liver disease | Health
31. (85) Prescription Cannabidiol CBD Oil Market to Hit US$ 190.9 Billion by 2032 at 23.48% CAGR
32. (85) TPS Cannabis News – StratCann
33. (85) InMed Pharmaceuticals Shifts Focus to Therapeutic Programs, Ends BayMedica’s Non …
34. (85) Cannabis Extracts Significantly Reduce Myofascial Pain | Trending – Labroots
35. (85) Pediatricians warn about cannabis use disorder, kids’ easy access to the drug – YouTube
36. (85) West Virginia House Passes Bill To Allocate Medical Marijuana Revenue, With Some …
37. (85) Study highlights positive, negatives of medical marijuana – WKRN News 2
38. (85) The science behind roadside THC testing and diving into SGI’s zero-tolerance policy – Global News
39. (85) Mom’s homemade medical cannabis recipe now being sold at Georgia dispensaries
40. (85) ‘Pot for Potholes Act’ aims to legalize marijuana in Tennessee and distribute taxes to repair …
41. (85) One of Colorado’s Largest Dispensary Chains Agrees to Buyout – Denver Westword
42. (85) Cannabis legalization driving increases in marijuana use among US adults with historically … – MSN
43. (85) Ohio Department of Commerce recalls certain marijuana gummies lacking THC symbol … – Facebook
44. (85) Perceptions of the relative harmfulness of marijuana and alcohol among adults in Oregon.
45. (84) What’s Really Happening With Cannabis ETF MSOS? – The Dales Report
46. (82) Study reveals cannabis compounds reduce threat of fatty liver disease – Daily Journal
47. (82) Scientists are raising new concerns about marijuana use in teens – KPBS
    Research continues to build a concerning picture around adolescent cannabis use and its association with elevated risk for psychiatric conditions, including psychosis, depression, and anxiety disorders. The developing brain, particularly during the teenage years, appears to be especially vulnerable to the neurochemical disruptions that cannabinoids can produce, with THC’s interaction with the endocannabinoid system potentially altering normal neurodevelopmental trajectories. Clinicians and public health researchers are increasingly calling for clearer communication about these risks, particularly as cannabis potency has risen substantially and cultural perception of harm has declined among younger populations.
48. (82) Clinical Trial: Cannabis Extracts Significantly Reduce Myofascial Pain – NORML
    Sublingual cannabis extract administration has demonstrated meaningful reductions in myofascial pain among patients with temporomandibular disorders, a condition historically resistant to conventional pharmacological approaches. The findings add to a growing body of evidence supporting cannabinoid-based interventions for chronic orofacial pain, where inflammation and central sensitization play significant roles. Sublingual delivery offers practical advantages in this population, including rapid mucosal absorption and the ability to titrate dosing with reasonable precision.
49. (81) Can the placenta predict schizophrenia risk? Lessons from prenatal cannabis exposure
    Emerging research is exploring whether placental biomarkers can serve as early indicators of schizophrenia risk, particularly in the context of prenatal cannabis exposure. THC crosses the placenta and can disrupt fetal neurodevelopment by interacting with the endocannabinoid system during critical windows of brain formation. This line of inquiry raises important questions about how prenatal THC exposure may prime neurobiological pathways associated with psychosis susceptibility later in life.
50. (81) Scientists are raising new concerns about marijuana use in teens – YouTube
    Adolescent cannabis use remains one of the most clinically significant concerns in cannabis medicine, as the developing brain is uniquely vulnerable to the effects of THC through at least the mid-twenties. Research consistently points to associations between early, frequent cannabis use and disruptions in neurodevelopmental trajectories, including effects on memory, attention, and emotional regulation. The concentration of THC in today’s products is substantially higher than in previous decades, which raises the stakes for any conversation about youth exposure and risk.
51. (78) When Legalization Meets Reality: High-THC Cannabis and Psychosis Risk
    A Psychology Today analysis argues that high-THC cannabis is linked to increased psychosis risk, particularly for young, heavy users, as potency has risen dramatically since the 1990s. The article calls for legalization paired with stricter potency controls and honest public education rather than framing cannabis as completely harmless.
52. (78) The Munchies’ Are Real and Could Benefit Those with No Appetite
    WSU’s official PNAS study found cannabis vapor universally increased food consumption in 82 volunteers regardless of BMI, sex, or dose, with beef jerky as the surprising top food choice. The research team aims to develop appetite therapies for HIV/AIDS and chemotherapy patients based on the brain-mediated mechanism.
53. (78) New Study in Pullman Shows ‘Munchies’ Might Help Those with Loss of Appetite
    A Pullman-based PNAS study used a whole-plant vapor approach with 82 community volunteers and parallel rat studies to prove the munchies are centrally brain-mediated. This translational design provides the strongest evidence yet for developing cannabis-based appetite therapies for clinical wasting syndromes.
54. (78) Kaiser Study Finds Higher Risk of Psychiatric Disorders in Teens Who Use Cannabis
55. (78) Adolescent Cannabis Use Linked to Doubling Risk of Psychotic and Bipolar Disorders
56. (78) Cannabis Use by Teenagers Doubles Their Risk of Developing Psychotic and Bipolar Disorders
57. (78) Kaiser Study Finds Higher Risk of Psychiatric Disorders in Teens Who Reported Cannabis Use
    Research from Kaiser Permanente examining teen cannabis use and psychiatric disorder risk adds to a growing body of evidence suggesting that the adolescent brain is particularly vulnerable to cannabinoid exposure during critical developmental windows. While association studies like these cannot establish causation, clinicians who work with cannabis medicine recognize that age of onset matters significantly, and the developing endocannabinoid system in teenagers responds very differently than in adults. This reinforces the importance of distinguishing between adult medical cannabis use under clinical supervision and unsupervised adolescent use, which carries a meaningfully different risk profile.
58. (78) A huge study finds a link between cannabis use in teens and psychosis later – NPR
    A large study has found an association between cannabis use during adolescence and increased risk of developing psychosis later in life. These findings underscore the importance of protecting the developing brain, as adolescents appear to be more vulnerable to cannabis-related neuropsychiatric outcomes than adults.
59. (78) Teen Cannabis Use Tied to Increase in Serious Mental Illness – Medscape
    Emerging research continues to reinforce what clinicians have observed for years: adolescent cannabis use, particularly during critical neurodevelopmental windows, is associated with a meaningful increase in risk for serious psychiatric conditions including psychotic and bipolar disorders. The developing brain remains uniquely vulnerable to exogenous cannabinoids, and the endocannabinoid system plays a central role in synaptic pruning and neural circuit maturation during the teenage years. This does not mean cannabis causes these conditions in every user, but it does underscore the importance of age-appropriate clinical guardrails and honest conversations about risk.
60. (78) Brain Researchers Finally Know Why Cannabis Use Increases Appetite – The Debrief
    The appetite-stimulating effects of cannabis, commonly known as “the munchies,” have long been observed clinically but the precise neurological mechanisms were not well characterized until recently. Research has now identified how cannabinoids interact with specific brain circuits to drive increased appetite, independent of the type or palatability of food available. This distinction is clinically meaningful because it suggests the effect is centrally driven rather than a response to sensory reward or food preference.
61. (78) Teen Marijuana Use Doubles Chances of Future Psychotic Disorders, Study Finds
    Research examining adolescent cannabis use has consistently identified a meaningful association between early initiation and elevated risk for psychotic spectrum disorders in adulthood, with the biological vulnerability of the developing adolescent brain playing a central role in this relationship. The endocannabinoid system undergoes significant maturation throughout adolescence, and exogenous cannabinoids introduced during this window appear to disrupt neurodevelopmental trajectories in ways that can have lasting psychiatric consequences. Potency of the cannabis product matters considerably here, as contemporary high-THC formulations represent a substantially different exposure profile than products studied in earlier decades.
62. (78) The association between cannabis use and brain reward anticipation: a 12-month … – Nature
    Research examining cannabis use and brain reward circuitry has produced inconsistent results, with some studies suggesting blunted responses to non-drug rewards and others showing minimal or no effect. The complexity likely stems from variables including frequency of use, age of initiation, cannabinoid content, and individual neurobiological differences that are difficult to control across study populations. Longitudinal designs tracking participants over time offer a more rigorous framework for understanding whether reward processing changes precede cannabis use, follow from it, or reflect a bidirectional relationship.
63. (78) THC levels in blood and urine are "unreliable" indicators of driving impairment – leafie
    The relationship between THC concentration in biological fluids and actual driving impairment is far more complex than a simple number can capture. THC is highly lipophilic, meaning it distributes rapidly into tissues and does not remain in blood proportionally to psychoactive effect, which makes blood levels a poor proxy for functional intoxication. Unlike alcohol, where blood concentration correlates reasonably well with impairment, cannabis pharmacokinetics vary dramatically based on frequency of use, individual metabolism, tolerance, and the presence of other cannabinoids.
64. (78) Study Links Prenatal Cannabis Exposure To Schizophrenia – New Telegraph
    Emerging research suggests that prenatal cannabis exposure may leave measurable biological signatures in placental tissue that are associated with increased schizophrenia risk in offspring. The placenta acts as a dynamic interface between maternal and fetal environments, and cannabinoids can cross this barrier and influence fetal neurodevelopment during critical windows of brain formation. These findings add biological plausibility to epidemiological signals that have long suggested a connection between gestational cannabis use and downstream psychiatric vulnerability in children.
65. (78) The Endocannabinoid System’s Contribution to Placebo Analgesia – bioRxiv
    The endocannabinoid system appears to play a meaningful role in mediating placebo analgesia, suggesting that the brain’s expectation of pain relief may partially operate through the same cannabinoid signaling pathways activated by cannabis-based medicines. This finding adds biological plausibility to the long-debated question of how much overlap exists between expectation-driven pain relief and pharmacologically induced analgesia. Understanding this mechanism has implications for how clinical trials are designed, how placebo responses are interpreted in cannabis pain studies, and how clinicians counsel patients about the neuroscience behind their treatment responses.
66. (78) Modulating the endocannabinoid system in alcohol use disorder: A translational systematic …
    The endocannabinoid system plays a central role in regulating reward circuitry, stress response, and impulse control, all of which are disrupted in alcohol use disorder. Cannabinoid receptors, particularly CB1 and CB2, along with endogenous ligands like anandamide and 2-AG, modulate dopaminergic and GABAergic pathways that drive craving, withdrawal, and relapse behavior. Research into ECS-targeted therapies, including FAAH inhibitors and neutral CB1 antagonists, represents a meaningful shift toward biologically informed treatment of addiction rather than purely behavioral approaches.
67. (78) Cannabis hyperemesis syndrome is on the rise: What symptoms to watch for – The Hill
    Cannabis hyperemesis syndrome (CHS) is a paradoxical condition in which chronic, heavy cannabis users develop cyclic episodes of severe nausea, vomiting, and abdominal pain, often relieved temporarily by hot showers or baths. The syndrome is frequently misdiagnosed for months or years because patients and clinicians alike associate cannabis with antiemetic properties, creating a counterintuitive diagnostic barrier. As high-potency THC products have become more widely available and socially normalized, the frequency of CHS presentations in emergency departments has increased, making clinician and patient awareness more urgent than ever.
68. (78) Association of Cannabis Use Disorder Versus Other Substance Use Disorders … – Psychiatry Online
    Research comparing cannabis use disorder to other substance use disorders is an important area of inquiry because it helps clinicians understand the relative psychiatric burden associated with problematic cannabis use in the context of a rapidly changing legal and cultural landscape. Propensity-score-matched study designs are valuable here because they attempt to control for the many confounding variables that make substance use populations inherently difficult to compare fairly. Understanding how cannabis use disorder stacks up against alcohol, opioid, or stimulant use disorders in terms of psychiatric outcomes can meaningfully inform screening, treatment prioritization, and public health messaging.
69. (78) Study Shows Lifetime Cannabis Use Not Associated with Cognitive Decline or Dementia …
    Emerging research from major academic institutions is challenging longstanding assumptions that cannabis use accelerates cognitive aging or increases dementia risk in older populations. The data suggest that lifetime exposure to cannabis, when examined in older adult cohorts, does not appear to correlate with measurable declines in cognitive function or elevated dementia incidence. This adds important nuance to how clinicians should counsel aging patients who use or are considering cannabis for symptom management.
70. (78) Study Finds No Link Between Lifetime Cannabis Use and Cognitive Decline in Older Adults
    Emerging longitudinal research is adding to a growing body of evidence suggesting that lifetime cannabis use in older adults does not appear to accelerate cognitive decline or meaningfully elevate dementia risk. This is clinically significant because older adults represent one of the fastest-growing demographics of cannabis users, and concerns about neurological harm have historically discouraged both patient use and physician engagement. The findings invite a more nuanced, evidence-based conversation about risk stratification in aging populations considering cannabis as part of their therapeutic toolkit.
71. (78) Israeli researchers find cannabis compounds could lead to 1st drug for fatty liver disease
    Researchers in Israel have identified specific cannabinoid compounds that show meaningful activity against non-alcoholic fatty liver disease, a condition affecting hundreds of millions of people worldwide that currently has no approved pharmaceutical treatment. The compounds appear to work through mechanisms involving hepatic fat accumulation, inflammation, and fibrosis pathways, which aligns with what the endocannabinoid system is already known to regulate in metabolic and liver tissue. This represents a significant step toward developing a targeted, cannabinoid-derived therapeutic rather than relying on whole-plant or broad-spectrum products.
72. (78) The Coming Divide in Cannabis: Why the U.S. Market Remains Out of Reach for Global Operators
73. (78) North Shore Dispensary opens in Duluth’s Lincoln Park – WDIO.com
74. (78) Study reveals cannabis compounds reduce threat of fatty liver disease | Health – News-Topic
    Emerging research suggests that cannabinoids, including both THC and CBD, may play a protective role against the development and progression of non-alcoholic fatty liver disease (NAFLD) by modulating hepatic inflammation, lipid metabolism, and fibrotic pathways through the endocannabinoid system. The liver expresses both CB1 and CB2 receptors, and while CB1 activation has historically been associated with pro-steatotic effects, selective CB2 stimulation appears to confer anti-inflammatory and antifibrotic benefits. This growing body of evidence positions the endocannabinoid system as a legitimate therapeutic target in metabolic liver disease, warranting further rigorous clinical investigation.
75. (76) Observational study on medical marijuana use seeks Arizona participants – KJZZ
    Observational research on medical cannabis is essential for building the real-world evidence base that controlled trials alone cannot provide, particularly given the diversity of conditions, products, and consumption patterns patients bring to clinical settings. Recruiting participants at the point of initiation allows researchers to capture baseline data and track outcomes longitudinally, which strengthens the quality of findings compared to studies that enroll patients already well into their cannabis use. Arizona’s participation in a national study expands geographic and demographic representation, which helps address longstanding concerns about whether cannabis research reflects the broader patient population.
76. (76) Cannabis compounds show promise in fighting fatty liver disease, scientists say – AZERTAC
    Emerging preclinical research is examining how non-psychoactive cannabinoids, particularly CBD and CBG, may influence hepatic lipid metabolism and reduce fat accumulation in liver tissue. These compounds appear to interact with endocannabinoid receptors and metabolic pathways involved in fatty acid synthesis and inflammation, offering a potential therapeutic avenue for metabolic-associated steatotic liver disease. While results from laboratory and animal models are encouraging, translating these findings into validated clinical protocols for human patients requires rigorous controlled trials to establish effective dosing, safety profiles, and long-term outcomes.
77. (75) Teenage Cannabis Users Twice as Likely as Non-Users to Develop Psychosis
    A JAMA Health Forum study of 463,396 adolescents found that cannabis use between ages 13–17 doubled the risk of developing psychotic and bipolar disorders by age 26. Cannabis use preceded psychiatric diagnoses by an average of 1.7–2.3 years, underscoring the vulnerability of the developing adolescent brain.
78. (75) Study: Teen Cannabis Use Linked to Double Psychosis Risk
79. (75) Full-Spectrum Cannabis Extract Shows Significant Pain Reduction in Chronic Neuropathic Pain
80. (75) Do anything, become nothing – The Morning News
    A new longitudinal study has found that adolescent cannabis use is associated with an increased risk of developing bipolar disorder and psychotic disorders later in life. These findings underscore the particular vulnerability of the developing brain to cannabis exposure, with age of onset identified as a clinically significant factor in downstream psychiatric outcomes.

Digest-Level Clinical Commentary